Lymphangioleiomyomatosis (LAM) Registry
NCT00005486 · Status: COMPLETED · Type: OBSERVATIONAL
Last updated 2016-02-18
Summary
To establish a registry of individuals with LAM by forming a consortium of six clinical centers and referring physicians who treat LAM patients.
Conditions
- Lung Diseases
- Lymphangiomyomatosis
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
lead NIH
Principal Investigators
-
Gerald Beck · The Cleveland Clinic
Eligibility
- Max Age
- 100 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1997-07-31
- Completion
- 2003-06-30
More Related Trials
-
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
NCT02509598 ·Status: COMPLETED ·Phase: PHASE2
-
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
NCT00345345 ·Status: COMPLETED ·Phase: PHASE2
-
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
NCT01410513 ·Status: COMPLETED ·Phase: PHASE1
-
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
NCT00923507 ·Status: RECRUITING
-
Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00081068 ·Status: WITHDRAWN ·Phase: PHASE2
-
Lymphoma Follow-up
NCT00744120 ·Status: COMPLETED
-
Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry
NCT04587388 ·Status: RECRUITING
-
Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma
NCT01307605 ·Status: TERMINATED ·Phase: PHASE2
-
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
NCT01447056 ·Status: COMPLETED ·Phase: PHASE1
-
B-Cell Hematologic Malignancy Vaccination Registry
NCT02298816 ·Status: WITHDRAWN
-
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
NCT00294632 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology
NCT01310946 ·Status: UNKNOWN
-
Registry Study for Talimogene Laherparepvec
NCT02173171 ·Status: COMPLETED
-
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
NCT04982471 ·Status: TERMINATED
-
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
NCT01472562 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma
NCT05464823 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The Lymphoma and Leukemia Society Amended COVID-19 Registry
NCT04794387 ·Status: COMPLETED
-
Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma
NCT05260619 ·Status: RECRUITING ·Phase: PHASE2
-
A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era
NCT04624971 ·Status: UNKNOWN
-
The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.
NCT03868527 ·Status: RECRUITING
-
Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
NCT05898477 ·Status: RECRUITING
-
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00005609 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
NCT00490529 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Localized Low Grade Lymphomas
NCT00536458 ·Status: COMPLETED ·Phase: PHASE3
-
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
NCT01754857 ·Status: COMPLETED ·Phase: PHASE2